MedTrace Logo

CTS-1027 in Interferon-Naive Hepatitis C Patients

NCT00925990 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 70

Last updated 2012-03-27

Study results available
· View outcomes & findings →

Summary

The study is intended to determine whether CTS-1027 either alone or in combination with ribavirin is safe and effective in Hepatitis C patients who have not previously been treated with interferon.

Conditions

  • Hepatitis C

Interventions

DRUG

ribavirin

200 mg capsules, either 1000 or 1200 mg taken twice daily for up to 24 weeks

DRUG

CTS-1027

5 and 10 mg tablets, 15 mg taken twice daily, for up to 24 weeks

DRUG

Placebo for ribavirin

Capsules identical to ribavirin in appearance containing inactive ingredients

Sponsors & Collaborators

  • Conatus Pharmaceuticals Inc.

    lead INDUSTRY

Principal Investigators

  • Erin Castelloe, MD · Conatus Pharmaceuticals Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-06-30
Primary Completion
2010-05-31
Completion
2010-07-31

Countries

  • United States
  • Puerto Rico

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00925990 on ClinicalTrials.gov